Styliani Kokoris

Dr. Styliani Kokoris


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2001 in JAMA
Verified
Journal Article
Closed access
PDF file
JIJohn P. A. Ioannidis
John P. A. Ioannidis
AHAnna-Bettina Haidich
Anna-Bettina Haidich
MPMaroudia Pappa
Maroudia Pappa
NPNikos Pantazis
Nikos Pantazis
SKStyliani Kokoris
Styliani Kokoris
JLJoseph Lau
Joseph Lau
ContextThere is substantial debate about whether the results of nonrandomized studies are consistent with the results of randomized controlled trials on the same topic.ObjectivesTo compare results of randomized and nonrandomized studies that evaluated medical interventions and to examine characteristics that may explain discrepancies between randomized and nonrandomized studies.Data SourcesMEDLINE (1966–March 2000), the Cochrane Library (Issue 3, 2000), and major journals were searched.Study SelectionForty-five diverse topics were identified for which both randomized trials (n = 240) and nonrandomized studies (n = 168) had been performed and had been considered in meta-analyses of binary outcomes.Data ExtractionData on events per patient in each study arm and design and characteristics of each study considered in each meta-analysis were extracted and synthesized separately for randomized and nonrandomized studies.Data SynthesisVery good correlation was observed between the summary odds ratios of randomized and nonrandomized studies (r = 0.75; P<.001); however, nonrandomized studies tended to show larger treatment effects (28 vs 11; P = .009). Between-study heterogeneity was frequent among randomized trials alone (23%) and very frequent among nonrandomized studies alone (41%). The summary results of the 2 types of designs differed beyond chance in 7 cases (16%). Discrepancies beyond chance were less common when only prospective studies were considered (8%). Occasional differences in sample size and timing of publication were also noted between discrepant randomized and nonrandomized studies. In 28 cases (62%), the natural logarithm of the odds ratio differed by at least 50%, and in 15 cases (33%), the odds ratio varied at least 2-fold between nonrandomized studies and randomized trials.ConclusionsDespite good correlation between randomized trials and nonrandomized studies—in particular, prospective studies—discrepancies beyond chance do occur and differences in estimated magnitude of treatment effect are very common.

1 February 2000 in The American Journal of Medicine
Verified
Journal Article
Closed access
SKStyliani Kokoris
Styliani Kokoris
JIJohn P.A Ioannidis
John P.A Ioannidis
MVMichalis Voulgarelis
Michalis Voulgarelis
ATAthanasios G Tzioufas
Athanasios G Tzioufas
HMHaralampos M Moutsopoulos
Haralampos M Moutsopoulos

1 March 2000 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MVMichalis Voulgarelis
Michalis Voulgarelis
SKStyliani Kokoris
Styliani Kokoris
JIJohn P A Ioannidis
John P A Ioannidis
ATAthanasios G Tzioufas
Athanasios G Tzioufas
DKDespina Kyriaki
Despina Kyriaki
HMHaralampos M Moutsopoulos
Haralampos M Moutsopoulos
OBJECTIVE To study the prevalence of different causes of anaemia in patients with systemic lupus erythematosus (SLE) and their associations with immunological and clinical parameters and to evaluate the contribution of erythropoietin (Epo) and anti-erythropoietin (anti-Epo) autoantibodies to the development of SLE anaemia. METHODS 132 SLE patients with anaemia (defined as haemoglobin of 12 g/dl or less for women and 13.5 g/dl or less for men) from among a total of 345 consecutive SLE patients were prospectively enrolled into the study. Standard haematological and immunological tests were performed and serum Epo and anti-Epo antibodies were assayed. RESULTS The identified causes were anaemia of chronic disease (ACD) n=49 (37.1%), iron deficiency anaemia (IDA) n=47 (35.6%), autoimmune haemolytic anaemia (AHA) n=19 (14.4%) and other causes n=17 (12.9%). There was significant heterogeneity in the severity of anaemia between the four groups (p<0.01) with AHA cases being on average more severe. The proportion of patients with anticardiolipin antibodies, low complement levels and anti-dsDNA differed significantly among the four groups; these markers were particularly common in patients with AHA, and uncommon in patients with IDA. Twenty one of 100 tested patients had anti-Epo antibodies. Such antibodies were seen practically only in patients with ACD (odds ratio 3.1, p=0.041) and in patients with high lupus activity (ECLAM) scores (odds ratio 1.27 per point, p=0.055). Epo response was inadequate in 42.4% and 41.2% of patients with ACD and AHA, respectively. CONCLUSIONS Anaemia in SLE usually takes the form of ACD and IDA, however autoimmune haemolysis is not uncommon. SLE patients with different causes of anaemia differ in regard to several immunological parameters. Epo response is blunted in anaemic SLE patients, particularly those with ACD and AHA.

4 April 2007 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
MKMarie‐Christine Kyrtsonis
Marie‐Christine Kyrtsonis
Theodoros VassilakopoulosTheodoros Vassilakopoulos
Theodoros Vassilakopoulos
NKNicoletta Kafasi
Nicoletta Kafasi
SSSotirios Sachanas
Sotirios Sachanas
TTTatiana Tzenou
Tatiana Tzenou
GPGerassimos Alexander Pangalis
Gerassimos Alexander Pangalis
Summary: The prognostic value of baseline serum free light chain ratio (sFLCR) was investigated in 94 multiple myeloma (MM) patients. sFLCR was calculated as κ/λ or λ/κ, depending on the patients’ dominating monoclonal light chain. Median baseline sFLCR was 3·57 in κ‐MM patients, 45·09 in λ‐MM. ‘High’ sFLCR (≥ the observed median value for κ‐ and λ‐MM respectively) correlated with elevated serum creatinine and lactate dehydrogenase, extensive marrow infiltration and light chain type MM. The 5‐year disease‐specific survival was 82% and 30% in patients with sFLCR lower than and equal or greater than the median, respectively (P = 0·0001). sFLCR was an independent prognostic factor.

26 January 2012 in The Oncologist
Verified
Journal Article
Closed access
Theodoros VassilakopoulosTheodoros Vassilakopoulos
Theodoros Vassilakopoulos
GPGerassimos A. Pangalis
Gerassimos A. Pangalis
AKAndreas Katsigiannis
Andreas Katsigiannis
SPSotirios Papageorgiou
Sotirios Papageorgiou
NCNikos Constantinou
Nikos Constantinou
MAMaria K. Angelopoulou
Maria K. Angelopoulou
Learning Objectives: After completing this course, the reader will be able to: Describe the effect of the addition of rituximab to standard CHOP chemotherapy on the outcome of patients with primary mediastinal large B-cell lymphoma.Explain potential changes in the use of radiotherapy and aggressive chemotherapy in the rituximab era.This article is available for continuing medical education credit at CME.TheOncologist.comMore aggressive treatment approaches (methotrexate, cytarabine, cyclophosphamide, vincristine, prednisone, and bleomycin [the MACOP-B regimen] or consolidation with high-dose therapy and autologous stem cell transplantation) have been considered to be superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with primary mediastinal large B-cell lymphoma (PMLBCL). Rituximab-CHOP (R-CHOP) is the standard of care for diffuse large B-cell lymphoma, whereas efficacy in PMLBCL has not been adequately confirmed.Patient and Methods.: Seventy-six consecutive PMLBCL patients who received R-CHOP with or without radiotherapy (RT) were compared with 45 consecutive historical controls treated with CHOP with or without RT. Baseline characteristics of the two groups were balanced.Results.: The rate of early treatment failure was much lower with R-CHOP with or without RT (9% versus 30%; p = .004). The 5-year freedom from progression rate after R-CHOP with or without RT was 81%, versus 48% for CHOP with or without RT (p < .0001). The 5-year event-free survival rates were 80% and 47% (p < .0001) and the 5-year overall and lymphoma-specific survival rates were 89% and 69% (p = .003) and 91% and 69% (p = .001), respectively, with only seven of 76 lymphoma-related deaths. Among R-CHOP responders, 52 of 68 received RT.Conclusions.: Based on these results, most patients with PMLBCL appear to be cured by R-CHOP in 21-day cycles with or without RT, which could be the current standard of care. Therefore, the need for more aggressive treatment strategies is questionable unless high-risk patients are adequately defined. Further studies are required to establish the precise role of RT.

22 January 2022 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
PAPanagiotis G. Asteris
Panagiotis G. Asteris
Eleni GavriilakiEleni Gavriilaki
Eleni Gavriilaki
TTTasoula Touloumenidou
Tasoula Touloumenidou
EKEvaggelia‐Evdoxia Koravou
Evaggelia‐Evdoxia Koravou
MKMaria Koutra
Maria Koutra
AAAchilles Anagnostopoulos
Achilles Anagnostopoulos
There is an unmet need of models for early prediction of morbidity and mortality of Coronavirus disease‐19 (COVID‐19). We aimed to a) identify complement‐related genetic variants associated with the clinical outcomes of ICU hospitalization and death, b) develop an artificial neural network (ANN) predicting these outcomes and c) validate whether complement‐related variants are associated with an impaired complement phenotype. We prospectively recruited consecutive adult patients of Caucasian origin, hospitalized due to COVID‐19. Through targeted next‐generation sequencing, we identified variants in complement factor H/CFH, CFB, CFH‐related, CFD, CD55, C3, C5, CFI, CD46, thrombomodulin/THBD, and A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS13). Among 381 variants in 133 patients, we identified 5 critical variants associated with severe COVID‐19: rs2547438 (C3), rs2250656 (C3), rs1042580 (THBD), rs800292 (CFH) and rs414628 (CFHR1). Using age, gender and presence or absence of each variant, we developed an ANN predicting morbidity and mortality in 89.47% of the examined population. Furthermore, THBD and C3a levels were significantly increased in severe COVID‐19 patients and those harbouring relevant variants. Thus, we reveal for the first time an ANN accurately predicting ICU hospitalization and death in COVID‐19 patients, based on genetic variants in complement genes, age and gender. Importantly, we confirm that genetic dysregulation is associated with impaired complement phenotype.